AdaptHealth price target raised to $14 from $11 at RBC Capital

RBC Capital raised the firm’s price target on AdaptHealth (AHCO) to $14 from $11 and keeps an Outperform rating on the shares after its Q4 earnings beat. The company saw a strong finish to 2024 and gave solid initial guidance, the analyst tells investors in a research note. Early signs that the strategic overhaul to the Diabetes business announced last quarter may be taking hold, the firm adds.